Corona Remedies Ltd. Company History and Annual Growth Details

Our Company was originally incorporated as ‘CORONA Remedies Private Limited’, a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to ‘CORONA Remedies Limited’. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.

Major events and milestones:
2004
- Launch of first division, later named as ‘Pioneer’ division in 2010

2005
- Launch of division (multispeciality): Xemx

2007
- Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh

2008
- Launch of division (gynaecology): Aarush

2013
- Launch of division (cardioloy): Wellness

2016
- Purchased the trademarks “Stelbid” and “Vitneurin” from Glaxo Group Limited
- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited

2018
- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis
- Acquired the trademarks “Obimet”, “Obimet-GX”, “Obimet SR”, “Obimet-V” “Triobimet” and “Thyrocab” (within India) from Abbott India Limited

2020
- Entered into a strategic alliance with La Chandra Pharmalab Private Limited

2021
- Commencement of production at the manufacturing plant at Ahmedabad, Gujarat

2022
- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris

2023
- Launch of division (urology): Blaze
- Purchased the trademark “Myoril” (in India) from Sanofi Healthcare India Private Limited
- Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat